Evommune, Inc.

NYSE:EVMN

Biotechnology

Healthcare
$7.02 -0.82%

-$0.17 today

Market cap
$290.28M
Beta
0.10
P/E (TTM)
-9.1
EPS (TTM)
-$2.26
52W Low $13.89High $33.20

Volume 0.90M

Average 0.38M

EVMN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Evommune, Inc.NYSE: EVMN

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$21.33M, compared with -$14.18M a year earlier. Trailing-twelve-month EBITDA was -$74.62M.

Context

  • EBITDA amounted to 519.1% of revenue in FY2025, down 416.4 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 2 fiscal years.
  • FY2025 was the largest annual figure in the 3 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of -$18.86M (+72.0%) for the fiscal year ending Dec 2026, a step up from the -3.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$21.33M+23.7% QoQ
Last fiscal yearDec 2025
-$67.48M-3.0% YoY
LTMMar 2026
-$74.62M— YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-50.4%-78.9%-28.4 pp
1 year-3.0%+72.0%+75.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(67.48M) USD
Year-over-year change
-3.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How EVMN compares with its peers on the latest reported figures

  • EVMN's LTM Mar 2026 EBITDA of -$74.62M is the 7th highest of the 10 companies compared; the peer median is -$33.82M.
  • EBITDA amounts to 746.2% of revenue for EVMN, versus a peer median of 94.3%.
EVMN Competitors Peer median
EBITDA for EVMN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$274.03M +696.5%+33.4%94.3%
FTREFortrea Holdings Inc.LTM Jun 2026$81.2M +109.5%—3.0%
ZYMEZymeworks Inc.LTM Sep 2026$57.08M +205.8%—21.5%
CDXSCodexis, Inc.LTM Mar 2026-$22.06M +62.9%—28.2%
OABIOmniAb, Inc.LTM Mar 2026-$33.82M +24.4%—117.0%
CLYMClimb Bio, Inc.LTM Mar 2026-$52.66M +43.4%——
EVMNEvommune, Inc.LTM Mar 2026-$74.62M ——746.2%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$84.44M -35.4%——
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026-$147.92M -653.3%—97.9%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-$260.06M -79.4%—3415.1%
Peer median (excluding EVMN) -$33.82M+43.4%+33.4%94.3%

Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5M7M13M
Cost of Revenue1M1.29M0
Gross Profit4M5.71M13M
Gross Margin80.0%81.6%100.0%
Research & Development32M64.24M74.04M
Selling, General & Admin9.85M11.48M20.03M
Operating Expenses41.85M75.73M94.07M
Depreciation & Amortization1M1.29M1.39M
EBITDA(33M)(65.49M)(67.48M)
EBITDA Margin-659.9%-935.5%-519.1%
Operating Income(37.85M)(70.01M)(81.07M)
Operating Margin-757.0%-1000.2%-623.6%
Interest Income3.86M3.24M3.32M
Interest Expense58K34K0
Other Income / Expenses3.8M3.2M12.2M
Income Before Tax(34.05M)(66.81M)(68.87M)
Pre-Tax Margin-681.1%-954.4%-529.8%
Income Tax Expense000
Net Income(34.05M)(66.81M)(68.87M)
Net Margin-681.1%-954.4%-529.8%
EPS (Basic)(1.13)(2.27)(2.18)
EPS (Diluted)(1.13)(2.27)(2.18)
Weighted Avg Shares30.08M30.08M31.52M
Weighted Avg Shares (Diluted)30.08M30.08M31.52M

Evommune, Inc.

NYSE:EVMN

Intrinsic Alpha fair value

Locked

Current Price

$7.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.